56 / 74 · 0:57 · Original AXON film
Zenagamtide / amycretin
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Zenagamtide = former amycretin
Zenagamtide, previously called amycretin, combines GLP-1 and amylin receptor activity within one molecule. Following both names helps keep the research record connected. [1] [2]
Oral phase 1 | 144 participants
A 2025 first-in-human randomized trial studied oral amycretin in 144 participants. The main questions concerned safety, tolerability, and how the body handled the compound. [1] [2]
Early safety and exploratory outcomes
Gastrointestinal events were common, and body-weight changes were explored. Early findings can support further trials without establishing a complete long-term benefit and risk profile. [1] [2]
Separate formulations, separate evidence
Oral and injectable formulations have separate study histories. Neither a shared name nor promising early results makes their effects interchangeable or establishes equivalence to a product outside the clinical program. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Amycretin investigators (2025): First-in-human phase 1 trial of oral amycretin →144 participants, oral formulation, early safety/tolerability and gastrointestinal events; exploratory weight outcomes.
- Novo Nordisk (2026): Cardiometabolic pipeline update for EASD 2026 →Zenagamtide formerly known as amycretin; unimolecular GLP-1 and amylin receptor agonist.
